Author Archives: Millie Nelson

Takeda loans J&J CDMO space to support COVID vaccine roll out

IDT Biologika will use capacity reserved for Takeda’s dengue vaccine candidate to provide fill-finish for Johnson & Johnson’s COVID-19 single-shot jab. Contract development manufacturing organization (CDMO) IDT Biologika had been contracted to use its Dessau site in Germany to manufacture Takeda’s dengue vaccine candidate, TAK-003. However, the facility will now be dedicated to filling and packaging J&J’s vaccine, which received US Food and Drug Administration (FDA) approval in February this year. J&J’s vaccine will be manufactured at the Dessau site…

Lonza dedicates suite to make Altimmune’s nasal COVID-19 vaccine

Lonza will commission a dedicated suite at its Houston, US facility for supply of Altimmune’s AdCOVID, a nasal COVID-19 vaccine that entered Phase I trials last month. Last November, Altimmune entered an agreement which meant that Lonza would provide commercial production capacity for AdCOVID from its Houston, US, site. Now, Altimmune has expanded its manufacturing partnership with lonza by adding capacity and stability through its own dedicated suite. “Our recently inaugurated Houston facility is our center of excellence for process…

Ins & Outs: Ex-Lonza CEO joins Recipharm, plus changes at Moderna

Marc Funk has joined CDMO Recipharm as its new CEO, while Moderna pinches Novartis’s chief legal officer. Meanwhile, there are high level changes at Univercells Technologies. It’s lovely to have you here for another BioProcess Insider’s, Ins & Outs. This week, Marc Funk announced on LinkedIn  that he has joined Recipharm as CEO. Funk has replaced contract development manufacturing organization (CDMO) Recipharm’s former CEO, Thomas Eldered who had held this position since 2008. “It is a great pleasure to be…

Industry hot for cold chain technologies, says thermal packaging firm

Cold Chain Technologies has scaled-up capacity after seeing an unprecedented demand for its services during the coronavirus pandemic. The thermal packaging solutions company, Cold Chain Technologies is part of the US government’s Operation Warp Speed (OWS) vaccine distribution plan and director of Corporate Development, Jamie Chasteen told BioProcess Insider it has seen a “huge bump” in demand since COVID-19. To meet this demand, the firm opened a manufacturing plant in less than eight weeks in Lebanon, Tennessee in November 2020…

ConserV Bioscience and eTheRNA to develop HIV vaccine

ConserV Bioscience and eTheRNA will share their expertise to develop an mRNA-based vaccine for HIV. The partnership will bring together ConserV’s services in identifying protective antigens and eTheRNA’s TriMix immunostimulatory mRNA technology and novel lipid nanoparticle encapsulation technologies. “We will first collaborate on an mRNA vaccine against HIV,” Tim Van Assche, director of Business Development and Alliance Management at eTheRNA Immunotherapies told BioProcess Insider. “In case results are positive, the collaboration will be extended to other mRNA vaccine formulations based…

GSK expands its manufacturing capacity at CGT Catapult

Cell and Gene Therapy Catapult says GlaxoSmithKline is expanding its clinical trial manufacturing capacity in Stevenage, UK to drive its gene therapy pipeline.  No financial details have been disclosed, however through this agreement GSK is set to leverage the Cell and Gene Therapy Catapult (CGT Catapult) Stevenage facility to improve its GMP cell processing network and, in turn, streamline technical transfer and develop its gene therapy pipeline. “GSK is the seventh collaborator to join and this increases further the breadth…

Univercells Technologies teams with High Purity New England for distribution

High Purity New England (HPNE) will market and sell Univercells Technologies’ products in the US after the two firms enter an agreement. No financials are connected to the agreement, however HPNE is now an authorized distributor of the firm’s technology offerings, which includes the Nevoline Upstream platform, the scale-X carbo system, and the scale-X hydro system. “The goal is to increase reach, expand the sales pipeline and further build the supply and service organization, recognizing the importance of being closer…

Novartis: Kundl shines bright for CureVac’s COVID vaccine

Novartis has invested €20 million ($23.8m) to service the CureVac deal and says up to 100 jobs will be created at its Kundl site in Austria.   Last week, Novartis became the latest firm to partner with CureVac to help manufacture its COVID-19 candidate, CVnCoV, at Novartis’ site in Kundl, Austria. The firm plans to manufacture up to 50 million doses by the end of 2021 and, potentially, a further 200 million doses by 2022. A spokesperson for Novartis told…

Going Dutch: Intravacc paves way for in-country vaccine production

CDMO Intravacc has started a concept design for a so-called ‘Multi-Purpose Vaccine Production Plant’ in response to COVID-19. Dutch contract development manufacturing organization (CDMO) Intravacc has signed a letter of intent alongside Bilthoven Biologicals, Poonawalla Science Park and Alt Foundation to begin developing a Multi-Purpose Vaccine Production Plant (MPVPP) at Utrecht Science Park, Bilthoven. According to Intravacc, the coronavirus pandemic has exposed the vulnerability of the Netherlands regarding the development and manufacturing of vaccines for its own population.  The firm…

Fujifilm says Denmark expansion meets continued CDMO demand

Fujifilm Diosynth Biotechnologies says the continual growth of the biopharma CDMO market means its Danish site will help meet industry demands as it begins its $928 million cell culture expansion project. In June 2020, the firm announced plans to invest $928 million to double capacity at the Danish site it acquired from Biogen in 2019. The capacity was 90,000 L and the expansion (which started last week) will boast another six large-scale stainless-steel tanks, giving a total capacity of 240,000…